Department of Emergency Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88, Olimpic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Department of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
BMC Med. 2020 Dec 14;18(1):390. doi: 10.1186/s12916-020-01875-5.
Clinical decision-making of invasive high-intensity care for critically ill stage IV cancer patients in the emergency department (ED) is challenging. A reliable and clinically available prognostic score for advanced cancer patients with septic shock presented at ED is essential to improve the quality of intensive care unit care. This study aimed to develop a new prognostic score for advanced solid cancer patients with septic shock available early in the ED and to compare the performance to the previous severity scores.
This multi-center, prospective cohort study included consecutive adult septic shock patients with stage IV solid cancer. A new scoring system for 28-day mortality was developed and validated using the data of development (January 2016 to December 2017; n = 469) and validation sets (January 2018 to June 2019; n = 428). The developed score's performance was compared to that of the previous severity scores.
New scoring system for 28-day mortality was based on six variables (score range, 0-8): vital signs at ED presentation (respiratory rate, body temperature, and altered mentation), lung cancer type, and two laboratory values (lactate and albumin) in septic shock (VitaL CLASS). The C-statistic of the VitaL CLASS score was 0.808 in the development set and 0.736 in the validation set, that is superior to that of the Sequential Organ Failure Assessment score (0.656, p = 0.01) and similar to that of the Acute Physiology and Chronic Health Evaluation II score (0.682, p = 0.08). This score could identify 41% of patients with a low-risk group (observed 28-day mortality, 10.3%) and 7% of patients with a high-risk group (observed 28-day mortality, 73.3%).
The VitaL CLASS score could be used for both risk stratification and as part of a shared clinical decision-making strategy for stage IV solid cancer patients with septic shock admitting at ED within several hours.
在急诊科(ED)对患有晚期癌症的危重症患者进行侵入性高强度治疗的临床决策具有挑战性。对于在 ED 出现感染性休克的晚期癌症患者,需要一种可靠且临床可用的预后评分,以改善重症监护病房的护理质量。本研究旨在为 ED 早期出现感染性休克的晚期实体癌患者开发一种新的预后评分,并将其与以前的严重程度评分进行比较。
这项多中心前瞻性队列研究纳入了连续的成年败血症休克合并 IV 期实体癌患者。使用开发(2016 年 1 月至 2017 年 12 月;n=469)和验证(2018 年 1 月至 2019 年 6 月;n=428)数据集来开发和验证用于 28 天死亡率的新评分系统。比较新评分系统与以前的严重程度评分的性能。
新的 28 天死亡率评分系统基于 6 个变量(评分范围,0-8):ED 就诊时的生命体征(呼吸频率、体温和意识改变)、肺癌类型以及败血症休克时的两个实验室值(乳酸和白蛋白)(VitaL CLASS)。VitaL CLASS 评分的 C 统计量在开发组为 0.808,在验证组为 0.736,优于序贯器官衰竭评估评分(0.656,p=0.01),与急性生理学和慢性健康评估 II 评分(0.682,p=0.08)相似。该评分可以识别 41%的低危组患者(观察到的 28 天死亡率为 10.3%)和 7%的高危组患者(观察到的 28 天死亡率为 73.3%)。
VitaL CLASS 评分可用于风险分层,也可作为 ED 内几小时内接受治疗的晚期实体癌合并败血症休克患者的临床决策制定策略的一部分。